{"id":"NCT02211209","sponsor":"Ionis Pharmaceuticals, Inc.","briefTitle":"The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12","primaryCompletion":"2016-12-19","completion":"2017-03-28","firstPosted":"2014-08-07","resultsPosted":"2022-04-13","lastUpdate":"2022-04-13"},"enrollment":67,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Familial Chylomicronemia Syndrome"],"interventions":[{"type":"DRUG","name":"Volanesorsen","otherNames":["ISIS 304801","ApoC-III","Approach","IONIS-APOCIIIRx"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Volanesorsen","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 52 weeks in participants with Familial Chylomicronemia Syndrome","primaryOutcome":{"measure":"Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3","timeFrame":"Baseline to 3 months","effectByArm":[{"arm":"Placebo","deltaMin":17.6,"sd":null},{"arm":"Volanesorsen","deltaMin":-76.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":40,"countries":["United States","Brazil","Canada","France","Germany","Hungary","Israel","Italy","Netherlands","South Africa","Spain","United Kingdom"]},"refs":{"pmids":["31390500","37164837","29748148","27271183"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":33},"commonTop":["Injection site erythema","Injection site pain","Abdominal pain","Nasopharyngitis","Headache"]}}